Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025/26 revenue SEK 16.72bn (-7.2%); operating margin 1.4%; net loss SEK 517.0m.
EBIT hit by impairments and restructuring; adjusted EBIT SEK 2.05bn; net debt SEK 3.19bn.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Elekta found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No confirmed data breaches, cyber incidents or regulator action involving Elekta found in HSH's search of the last 24 months. Unverified claims on ransomware leak-site trackers are not included. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Apr 2026: Elekta began a US FDA Class 2 recall of its Advanced Gynecological brachytherapy applicator after reports the intrauterine tube tip can detach. In Sep 2025 it also recalled Leksell Vantage stereotactic frames over paint flakes, which it said had not been seen clinically.
Contract delivery, go-lives, terminations and disputes.
Dec 2025: Elekta was named, with Varian and Accuray, as a supplier of the 28 new radiotherapy linear accelerators NHS Supply Chain is buying for 2025/26 through its framework, which reported £21.8m of savings.